Administration of neomycin resistance gene-marked EBV-specific cytotoxic T-lymphocytes as therapy for patients receiving a bone marrow transplant for relapsed EBV-positive Hodgkin disease

Hum Gene Ther. 2000 Jul 1;11(10):1465-75. doi: 10.1089/10430340050057530.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I

MeSH terms

  • Bone Marrow Transplantation / methods*
  • Cell Line
  • Drug Resistance, Neoplasm / genetics*
  • Feasibility Studies
  • Female
  • Genetic Therapy*
  • Herpesvirus 4, Human / genetics*
  • Herpesvirus 4, Human / immunology
  • Hodgkin Disease / therapy*
  • Humans
  • Male
  • Neomycin / metabolism*
  • Recurrence
  • T-Lymphocytes, Cytotoxic / metabolism*

Substances

  • Neomycin